Abstract
Preterm birth (PTB) is a leading cause of neonatal mortality and morbidity worldwide, and surviving infants are at increased risks of lifelong complications. PTB has been firmly linked to inflammation regardless of infection, specific aetiology or timing of birth. Deleterious inflammation is observed in maternal and fetal tissue, and correlates with the severity of perinatal complications. At present, PTB is treated with tocolytics as though it is exclusively a myometrial contractile disorder. These agents do not address underlying inflammatory processes and are thus vastly ineffective at improving neonatal outcomes. Of all inflammatory mediators, IL-1 is central to the pathophysiology of PTB and most adverse neonatal outcomes. We thus present herein a review of the various effects of IL-1 in utero, with a brief overview of its mechanism of action. We then discuss the potential of different IL-1-targeting agents based on pre-clinical testing in relevant models of PTB and neonatal inflammatory injuries.
Keywords: Interleukin-1, preterm labor, preterm birth, inflammation, neonatal injuries, neonatal mortality.
Current Pharmaceutical Design
Title:Preterm Birth and Neonatal Injuries: Importance of Interleukin-1 and Potential of Interleukin-1 Receptor Antagonists
Volume: 23 Issue: 40
Author(s): Mathieu Nadeau-Vallee, Dima Obari, Alexandra Beaudry-Richard, Estefania Marin Sierra, Alexandre Beaulac, Noemie Maurice, David M. Olson*Sylvain Chemtob*
Affiliation:
- Departments of Obstetrics and Gynecology, Pediatrics and Physiology, University of Alberta, Edmonton, T6G 2R3,Canada
- Departments of Pediatrics, Ophthalmology and Pharmacology, CHU Sainte-Justine Research Center, Montreal, H3T 1C5,Canada
Keywords: Interleukin-1, preterm labor, preterm birth, inflammation, neonatal injuries, neonatal mortality.
Abstract: Preterm birth (PTB) is a leading cause of neonatal mortality and morbidity worldwide, and surviving infants are at increased risks of lifelong complications. PTB has been firmly linked to inflammation regardless of infection, specific aetiology or timing of birth. Deleterious inflammation is observed in maternal and fetal tissue, and correlates with the severity of perinatal complications. At present, PTB is treated with tocolytics as though it is exclusively a myometrial contractile disorder. These agents do not address underlying inflammatory processes and are thus vastly ineffective at improving neonatal outcomes. Of all inflammatory mediators, IL-1 is central to the pathophysiology of PTB and most adverse neonatal outcomes. We thus present herein a review of the various effects of IL-1 in utero, with a brief overview of its mechanism of action. We then discuss the potential of different IL-1-targeting agents based on pre-clinical testing in relevant models of PTB and neonatal inflammatory injuries.
Export Options
About this article
Cite this article as:
Nadeau-Vallee Mathieu , Obari Dima , Beaudry-Richard Alexandra , Sierra Marin Estefania , Beaulac Alexandre , Maurice Noemie , Olson M. David *, Chemtob Sylvain *, Preterm Birth and Neonatal Injuries: Importance of Interleukin-1 and Potential of Interleukin-1 Receptor Antagonists, Current Pharmaceutical Design 2017; 23 (40) . https://dx.doi.org/10.2174/1381612823666170825145114
DOI https://dx.doi.org/10.2174/1381612823666170825145114 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The beneficial effect of Cape gooseberry juice on carbon tetrachloride-induced neuronal damage
CNS & Neurological Disorders - Drug Targets Systemic and CNS Inflammation Crosstalk: Implications for Alzheimer’s Disease
Current Alzheimer Research Disseminated Intravascular Coagulation in Leukemia and Sepsis
Vascular Disease Prevention (Discontinued) Local Activation and Systemic Dysregulation of T Lymphocytes in Sjögren’s Syndrome
Current Pharmaceutical Biotechnology Role of FK506 Binding Proteins in Neurodegenerative Disorders
Current Medicinal Chemistry Cytotoxicity and Toxicity to Animals and Humans of Ribosome-Inactivating Proteins
Mini-Reviews in Medicinal Chemistry Genomic Instability and Cancer
Current Molecular Medicine Antioxidant Food Supplements and Obesity-Related Inflammation
Current Medicinal Chemistry The Interaction between Arachidonic Acid Metabolism and Homocysteine
Endocrine, Metabolic & Immune Disorders - Drug Targets Regulatory Mechanisms of Chondrogenesis and Implications for Understanding Articular Cartilage Homeostasis
Current Rheumatology Reviews Targets for the Treatment of Erectile Dysfunction: Is NO/cGMP Still the Answer?
Recent Patents on Cardiovascular Drug Discovery A Review on the New Indication of Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in the Treatment of Coronavirus Disease 2019
Infectious Disorders - Drug Targets Evaluation of Inflammatory Biomarkers in Iranian Patients with Cystic Fibrosis
Current Respiratory Medicine Reviews Genetic Predisposition to Parkinson’s Disease and Cancer
Current Cancer Drug Targets Exploration of the Effect and Mechanism of ShenQi Compound in a Spontaneous Diabetic Rat Model
Endocrine, Metabolic & Immune Disorders - Drug Targets Lung Defence Mechanisms and Their Potential Role in the Prevention of Ventilator Associated Pneumonia
Current Respiratory Medicine Reviews Thoracic Aortic Aneurysm: Blood Pressure and Inflammation as Key Factors in the Development of Aneurysm Dissection
Current Pharmaceutical Design Heterocyclic Compounds as Inflammation Inhibitors
Current Medicinal Chemistry Characterization of the Clinical and Laboratory Features of Primary and Secondary Antiphospholipid Syndrome in a Cohort of Egyptian Patients
Current Rheumatology Reviews Non-Hodgkins Lymphoma: Review of Conventional Treatments
Current Pharmaceutical Biotechnology